216 related articles for article (PubMed ID: 17303473)
21. [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Mitsuyama S
Nihon Rinsho; 2007 May; 65 Suppl 5():78-83. PubMed ID: 17571369
[No Abstract] [Full Text] [Related]
22. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Kurtz TW; Pravenec M
J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
24. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Cardiovasc Drugs Ther; 2007 Aug; 21(4):317-8. PubMed ID: 17629779
[No Abstract] [Full Text] [Related]
25. Irbesartan treatment in hypertension.
Brown MJ
Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
[TBL] [Abstract][Full Text] [Related]
26. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
Unger T
Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
[TBL] [Abstract][Full Text] [Related]
27. Are angiotensin receptor blockers neuroprotective?
Thöne-Reineke C; Zimmermann M; Neumann C; Krikov M; Li J; Gerova N; Unger T
Curr Hypertens Rep; 2004 Aug; 6(4):257-66. PubMed ID: 15257859
[TBL] [Abstract][Full Text] [Related]
28. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
29. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
30. [Dosage equivalents of AT1-receptor antagonists available in Germany].
Dominiak P; Häuser W
Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
[No Abstract] [Full Text] [Related]
31. Angiotensin II antagonists: a new class of antihypertensive agent.
Waeber B; Brunner HR
Br J Clin Pract; 1996; 50(5):265-8. PubMed ID: 8794603
[TBL] [Abstract][Full Text] [Related]
32. Effects of telmisartan on metabolic syndrome components: a comprehensive review.
Imenshahidi M; Roohbakhsh A; Hosseinzadeh H
Biomed Pharmacother; 2024 Feb; 171():116169. PubMed ID: 38228033
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin receptor antagonists: focus on losartan.
Johnston CI
Lancet; 1995 Nov; 346(8987):1403-7. PubMed ID: 7475826
[No Abstract] [Full Text] [Related]
34. Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Ando H; Ushijima K; Hosohata K; Saito T; Fujimura A
Br J Clin Pharmacol; 2013 Feb; 75(2):415-22. PubMed ID: 22703472
[TBL] [Abstract][Full Text] [Related]
35. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M
Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.
Jover B; Mimran A
J Hypertens Suppl; 1994 Nov; 12(9):S3-9. PubMed ID: 7884582
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans PB; Wong PC; Chiu AT; Herblin WF; Benfield P; Carini DJ; Lee RJ; Wexler RR; Saye JA; Smith RD
Pharmacol Rev; 1993 Jun; 45(2):205-51. PubMed ID: 8372104
[No Abstract] [Full Text] [Related]
38. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
Kintscher U; Unger T
Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
[TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues.
Johnston CI; Risvanis J
Am J Hypertens; 1997 Dec; 10(12 Pt 2):306S-310S. PubMed ID: 9438774
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
